We studied the expression of the interleukin-2 (IL-2) receptor and the proliferative response to exogenous IL-2 of peripheral blood leukemic cells from patients with adult T cell leukemia (ATL) in order to see whether IL-2 receptor expressed on ATL cells is different from normal IL-2 receptor and whether it plays a role in the neoplastic growth in ATL.
Leukemic cells from 15 patients with ATL examined showed no or very poor proliferative response to various concentrations of immunoaffinity-purified IL-2, although they expressed Tac antigen (Ag). Radiolabeled IL-2 binding experiments demonstrated that ATL leukemic cells could bind IL-2, and they expressed both high and low affinity IL-2 receptors, although the number of high affinity IL-2 receptor was much less than that of low affinity IL-2 receptor and that of antiTac binding sites.
In contrast, leukemic T cells from a patient with T cell chronic lymphocytic leukemia (CLL), in whom HTLV-I infection was not demonstrated, responded as well as PHA-Pstimulated normal T cells, and their IL-2 receptors, unlike ATL cells, were modulated (down regulated) by anti-Tac antibody.
No differences were noted between ATL cells and normal activated T cells in one-dimensional sodium dodecyl sulfate polyacrylamide gel electrophoresis analysis of the II2 receptor.
Thus, leukemic cells in ATL spontaneously and continuously express IL-2 receptor, which appears to be abnormally regulated and unresponsive to IL-2. These results, taken together with those on normal IL-2 receptors on HTLV-I-negative T-CLL cells, suggest that abnormal expression of the IL-2 receptor in Introduction Adult T cell leukemia (ATL),' which has characteristic clinical and hematologic features and is endemic southwest of Japan (1) (2) (3) , is a leukemia of peripheral, mature, and OKT4(+) T cells (4) . Studies subsequent to the discovery and isolation of a novel human retrovirus, human T cell leukemia/lymphoma virus, type I (HTLV-I) (5, 6) , have demonstrated a close association between HTLV-I and the leukemogenesis of ATL (7) (8) (9) (10) , although the mechanism of the cell transformation that may be induced by HTLV-I infection remains unclear.
We previously reported that leukemic cells in ATL are derived from peripheral mature T cells with a helper/inducer subset phenotype and express Tac antigen (Ag) (interleukin-2 [IL-2] receptor) (4) that is recognized by anti-Tac monoclonal antibody (11) (12) (13) . Popovic et al. (14) also noted the strong expression of Tac Ag on cord blood cells that were transformed by co-culturing with HTLV-producing cell lines. A recent report by Waldmann et al. also showed that HTLV-positive ATL cells, but not HTLV-negative Sezary cells, express IL-2 receptors (15) . In addition, we found that Tac Ag on ATL cells, unlike those on normal activated T cells, is not modulated by anti-Tac antibody (16) , which suggests the abnormal regulation of Tac Ag expression in ATL cells. The proliferation of normal peripheral T cells initiated by antigen or lectin is mediated by IL-2, which is produced by activated T cells and binds to inducible IL-2 receptors. Further characterization of the IL-2 receptor on ATL cells is needed to understand whether it is merely a marker of ATL cells or if it is involved in their neoplastic growth.
In the present study, we examined the molecular size and IL-2 binding activity of IL-2 receptors expressed on peripheral blood leukemic cells from patients with ATL, and the proliferative response of ATL cells to exogenous IL-2, comparing those of normal activated T cells and HTLV-I negative leukemic T cells.
We will show that peripheral blood leukemic T cells in ATL respond very poorly to exogenous IL-2, although they express Tac antigen of similar molecular weight to that of normal activated T cells and can bind IL-2. In contrast, leukemic T cells from a patient with chronic lymphocytic leukemia which were negative for HTLV-I provirus integration, expressed Tac antigen and showed a good proliferative response to IL-2.
Methods
Patient population. 42 patients with ATL and one patient with chronic lymphocytic leukemia of T cell origin were studied. The age of ATL patients ranged from 24 to 76, and 25 of the 42 patients were male. The diagnosis of ATL was made on the basis of clinical features (2), hematologic characteristics (2), serum antibodies to ATL-associated antigens (6) in all cases, and the HTLV provirus integration in DNA of leukemic cells in seven cases. Peripheral white blood cell count ranged from 15,900 to 249,000/mm3.
The patient with T cell chronic lymphocytic leukemia (T-CLL) was a 54-yr-old male with generalized lymph node enlargement and a high white blood cell count (range, 29,200-100,000 cells/mm3). Peripheral blood smears showed lymphoid cells with nonconvoluted nuclei.
Cell separation and culture. Peripheral blood mononuclear cells were separated from heparinized blood by Ficoll-Hypaque density gradient centrifugation. Both fresh leukemic cells and frozen cells, which had been stored in liquid nitrogen, were used. The recovered cells with good viability (>85%) were used. More than 80% of the cells in the cell suspension examined were leukemic cells as determined by the morphological characteristics of cells on the May-Giemsa-stained slides.
Leukemic cells cultured from I to 7 d in RPMI 1640 medium containing 10% fetal calf serum (FCS) (M.A. Bioproducts, Walkersville, MD) or autologous serum or plasma were also examined for the expression and IL-2 binding of IL-2 receptor. Normal peripheral blood mononuclear cells cultured with 0.1% phytohemagglutinin-P (PHA-P) (Difco Laboratories, Detroit, MI) for 2-7 d were used for the quantitation of Tac antigen and for IL-2 binding assay. ATL-derived and HTLV-I-infected cell lines, MT-I (17) ahd HutlO2 (18), which were maintained with RPMI 1640 medium (Nissui Pharmaceutical Co., Ltd., Tokyo, Japan) containing 10% FCS, were also used.
Detection ofIL-2 receptor by immunofluorescence. Anti-Tac monoclonal antibody that recognizes human IL-2 receptor (13) was used to detect IL-2 receptor. Its production and characterization were described elsewhere (1 1, 13 Radiolabeled IL-2 binding assay. Escherichia coli-derived recombinant IL-2 was kindly provided by Takeda Chemical Industries Inc. (Osaka, Japan). The purity of recombinant IL-2 was >99.8%, and the biological activity which was comparable to Jurkat cell line-derived immunoaffinity-purified IL-2 was determined by the proliferation assay using IL-2-dependent cell lines and PHA-P-stimulated normal peripheral blood lymphocytes (data not shown). IL-2 was radiolabeled using '25I-Bolton and Hunter's reagents (B&H reagent, 2,000 Ci/mmol, monoiodinated, NEX-120, New England Nuclear, Boston, MA). Specific radioactivity of labeled IL-2 was 2,000-5,000 cpm/ng. Effective radioactivity bindable to cells was -90% of the total activity.
Radiolabeled IL-2 binding assay was performed according to the method described by Robb et al. (19, 20) with a slight modification. Cells were incubated at 370C in IL-2-free fresh RPMI 1640 medium twice for 60 min to promote dissociation and/or degradation of endogenously bound IL-2. Serial dilutions of radiolabeled IL-2 and 2-5 X 106 cells in a total volume of 0.5 ml of RPMI 1640 medium containing 25 mM Hepes, pH 7.2, and 10 mg/ml of bovine serum albumin (Armour Pharmaceutical Co., Kankakee, IL) were incubated at 370C for 60 min. After incubating, washing, and resuspending cells, 200 Ml of cell suspension in duplicate was centrifuged through a 150-Ml layer of a mixture of 20% olive oil and 80% Di-n-butyl phthalate.
The tips of the tubes containing the cell pellet were cut off and the radioactivity was counted in a gamma counter. Corp., Arlington Heights, IL) for the last 6 h, followed by precipitation onto glass fiber filters, and the radioactivity was counted by liquid scintillation. MT-i cells were cultured both at 5 X 104/ml and 2.5 X 101 cells/ml in a 96-well plate in the presence of IL-2.
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Tac Ag immunoprecipitated by anti-Tac antibody from labeled cell lysates was analyzed by one-dimensional SDS-PAGE according to the method described in detail previously (21 at an IL-2 concentration of 0.5 U/ml ranged from 0.2 to 6.5 in ATL leukemic cells and from 75 to 806 in PHA-Pstimulated normal T cells. MT-1 cells established from an ATL patient (17) did not respond to IL-2 in spite of the markedly enhanced expression of Tac Ag (Fig. 4, Table 1 ). Leukemic cells from a patient with T-CLL, on the other hand, showed a good proliferative response to IL-2, which was comparable with that of PHA-P-stimulated normal T cells (Fig. 4) .
We also studied ATL cells cultured for 3-7 d, which expressed more IL-2 receptors than fresh leukemic cells in order to assess whether their poor proliferative response of ATL leukemic cells were due to an inadequate number of IL-2 receptors on fresh leukemic cells. Cultured leukemic cells, The number of anti-Tac and IL-2 binding sites were determined by Scatchard analysis of radiolabeled anti-Tac and radiolabeled IL-2 binding experiments. * Peripheral blood leukemic cells from ATL patients were examined both after separated from blood or recovered from freshfrozen state and after cultured for 3-6 d.
however, still showed a poor response to exogenous IL-2 even after the number of cell surface anti-Tac binding sites increased (data not shown). In addition, peripheral blood leukemic cells from three patients with ATL who were examined did not respond to IL-2 even at a concentration of 32 U/ml (two patients) or 130 U/ml (one patient). Radiolabeled IL-2 binding. Unstimulated normal peripheral ATL blood lymphocytes and Tac-negative T or B cell lines did not bind significant amount of radiolabeled IL-2 (data not shown).
As radiolabeled anti-Tac binding, the reversibility of radiola- analysis demonstrated IL-2 receptors with two different affinities in PHA-P-stimulated normal peripheral lymphocytes, HTLV-I-infected cell lines (data not shown), and leukemic cells from ATL patients. Peripheral blood lymphocytes stimulated by PHA-P for 2-7 d exhibited 1,300-3,500 IL-2 receptors/cell with high affinity (K. = 2.6-6.9 X 10'°M-') and 8,000-25,500 receptors/cell with low affinity (K. = 3.7-8.8 X 108 M-l). In HutlO2 cells, the majority of IL-2 receptors were low affinity receptors. In ATL case M.S., fresh leukemic cells expressed 250/cell high and 2,250/cell low affinity IL-2 receptors. The leukemic cells cultured with medium for 5 d expressed 2,100/ cell high and 37,500/cell low affinity IL-2 receptors, the total of which was roughly equal to the number of anti-Tac binding sites (34,000/cell). Radiolabeled IL-2 binding assay of both fresh and short-term cultured leukemic cells from another ATL patient (case S.Y.) also showed both low and high affinity IL-2 receptors (data not shown), as in case M.S. No major differences were noted in the affinity of two classes of IL-2 receptors between ATL leukemic cells (Ka = 1.1 X 1010 M-1, 9.5 X 108 M-'), Hut 102 cells, and PHA-P-stimulated normal lymphocytes. These radiolabeled IL-2 binding experiments showed that both ATL leukemic cells and HTLV-I-infected cell lines expressed comparable number of high affinity IL-2 receptors to that of PHA-P-stimulated normal lymphocytes, which could bind IL-2 at the concentrations used in the proliferative response to IL-2, and also expressed a large number of low affinity IL-2 receptors.
Polyacrylamide gel analysis of IL-2 receptor on ATL leukemic cells. IL-2 receptors expressed on the surface of leukemic cells from five ATL patients were analyzed on onedimensional PAGE. No difference was observed among IL-2 receptors expressed on ATL leukemic cells, ATL-derived MT-1 cell line, and PHA-P-activated normal T cells (Fig. 7) . Apparent molecular weight of IL-2 receptors on ATL leukemic cells estimated on polyacrylamide gel was 60,000-65,000. 450 Uchiyama et al. In all cases of ATL examined and MT-1 cell line, one band with an apparent molecular weight of 60,000-65,000 was detected; it was identical to that seen in PHA-P-stimulated T cells.
Discussion
In the present study we showed that peripheral blood leukemic cells from patients with ATL express IL-2 receptor on their cell surface in the absence of known activators such as lectin, or antigens that induce IL-2 receptor on normal resting T cells. ATL leukemic cells, however, respond very poorly to exogenous IL-2, although they express a comparable or higher number of IL-2 receptors as detected by anti-Tac antibody and radiolabeled IL-2 binding experiments. They can bind radiolabeled IL-2, and their IL-2 receptors are not different from those on normal activated T cells, as determined by PAGE.
It is most unlikely that the majority of Tac Ag-positive cells detected by the immunofluorescence and flow cytometric analysis were contaminated normal lymphocytes because the majority of the cells stained and examined were leukemic cells and few Tac Ag-positive cells were detected in both fresh and short-term cultured normal peripheral blood lymphocytes. Demonstration of the IL-2 receptor on peripheral blood leukemic cells from 42 ATL patients examined in the present study, together with our previous findings (4, 16) and those of others (14, 15), clearly shows that leukemic T cells infected with HTLV-I express IL-2 receptors. HTLV-I-infected cultured cell lines such as MT-1 and HutlO2 especially express an augmented number of IL-2 receptors (12-21-fold more than PHA-P-stimulated T cells), as detected by binding assay using radiolabeled anti-Tac. HTLV-I infection is not always required for leukemic T cells to spontaneously express IL-2 receptors, as we detected IL-2 receptor on leukemic T cells from a T-CLL patient in which HTLV-I provirus integration into DNA of leukemic cells was not demonstrated. Nevertheless, it is likely that HTLV-I infection, directly or indirectly, induces enhanced IL-2 receptor expression, the mechanism of which remains to be clarified.
The mechanism underlying the increase of IL-2 receptor expression of leukemic cells from ATL patients during a shortterm culture remains unclear. It seems unlikely that this increase is due to the removal of the factor(s) which may be contained in the serum or plasma and inhibit the expression of IL-2 receptors in vivo, because the increase of IL-2 receptor expression was also observed when leukemic cells were cultured with medium containing autologous serum or plasma. Teshigawara et al. (22) have recently reported that HTLV-I-infected cell lines produce a factor termed ATL-derived factor (ADF), which augments IL-2 receptor expression. ADF may be produced by ATL leukemic cells during a short-term culture and may contribute to the increase of IL-2 receptor expression. Using complementary DNA encoding human IL-2 receptor, we are trying to study the change of the quantity of IL-2 receptor mRNA of ATL cells during the culture in order to determine whether the increase in the number ofIL-2 receptors is due to the actual enhancement of IL-2 receptor synthesis and whether ADF or ADF-like factors are involved in the enhancement of IL-2 receptor expression.
The initial finding of the very poor proliferative response of ATL leukemic cells was unexpected, because many cultured cell lines with HTLV-I provirus integration were established by culturing leukemic cells with IL-2 (14, 23). Our results, however, suggested that cultured cell lines from ATL patients were derived from residual nonleukemic T cells that were infected with HTLV-I and could respond to added IL-2. The recent report (24) analyzing the HTLV-I provirus integration site indicated that the populations of infected cells of fresh and long-term cultured cell lines from the same patient appeared to be different.
It is unlikely that the poor proliferative response of ATL leukemic cells to exogenous IL-2 is due to a small number of IL-2 receptors on fresh leukemic cells, because ATL leukemic cells bearing comparable or higher number of both high and low affinity IL-2 receptors after a short-term culture still remained unresponsive to > 10-fold excess concentration of IL-2, which can saturate high affinity IL-2 receptors. Leukemic T cells from a patient with T-CLL also responded well to IL-2 in spite of the lower number of IL-2 receptors on the cell surface. In addition, MT-1 and HutlO2 cells, derived from ATL patients, did not respond to IL-2 although they expressed 50-80-fold higher number of IL-2 receptors. A similar phenomenon was reported in the A431 cell line (25) . These cells derived from epidermoid carcinoma cells and, expressing a large number of epidermal growth factor receptors, do not respond to ordinary concentrations of epidermal growth factor (26, 27 We previously reported the abnormal regulation of Tac Ag on ATL leukemic cells (16) . In addition, the IL-2 receptor on ATL-derived and HTLV-I-infected MT-1 cell line is spontaneously phosphorylated, whereas IL-2 receptor on PHA-stimulated normal T cells is IL-2-dependently phosphorylated (Wano, Y., T. Uchiyama, N. Kobayoshi, M. Hatanaka, M. Maeda, J. Yodoi, and H. Uchino, submitted for publication). Taken together, leukemic cells in ATL spontaneously and continuously express an enhanced number of IL-2 receptors that appear abnormally regulated, unresponsive to IL-2, and IL-2-independently phosphorylated.
In contrast, leukemic T cells from a T-CLL patient in which HTLV infection was not demonstrated expressed IL-2 receptors, proliferated in response to purified IL-2, and their IL-2 receptor was modulated (down regulated) by anti-Tac antibody as normal IL-2 receptor on activated T cells (data not shown). These results suggest the close association between the abnormal expression of the IL-2 receptor and HTLV-I infection in ATL.
Several aspects of abnormally expressed IL-2 receptors in ATL leukemic cells previously reported (16) and demonstrated in the present study suggest that spontaneously, continuously, and unregulatably expressed IL-2 receptors may be responsible for the uncontrollable growth of ATL cells (30) . The autocrine hypothesis, in which IL-2 continuously produced by HTLV-I-infected mature T cells is considered to mediate the neoplastic growth by binding to IL-2 receptors induced on their own cell surface (31) , has been ruled out because of the lack of IL-2 gene expression in HTLV-I-infected cells (32) . In ATL, IL-2 receptors that are abnormally regulated, unresponsive to IL-2, and spontaneously (IL-2 independently) phosphorylated, may continuously generate growth signals that lead to the neoplastic growth of ATL cells. Recent studies demonstrating the structural and functional similarities between growth factor molecules or their receptors and oncogene products (33, 34) suggest the involvement of uncontrolled production of growth factors or uncontrolled receptor functions in the cell transformation. Further studies are required to clarify the mechanism of the IL-2 receptor expression in relation to HTLV-I infection, and to demonstrate directly the role of the IL-2 receptor in the proliferation of leukemic cells in ATL.
